Sugi Predict

Sugi Predict / Compounds / SCHEMBL1804321

SCHEMBL1804321

SCHEMBL1804321

O=C(O)C=Cc1cc(O)ccc1Br

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BACE1 P56817 4/20 0.62
▸ MIF P14174 1/20 0.59
▸ AKR1C3 P42330 1/20 0.54
▸ AKR1C2 P52895 1/20 0.54
▸ EIF2AK2 P19525 1/20 0.53
▸ CSNK2A2 P19784 1/20 0.53
▸ CSNK2B P67870 1/20 0.53
▸ CSNK2A1 P68400 1/20 0.53
▸ CA1 P00915 3/20 0.50
▸ CA2 P00918 3/20 0.50
▸ CA4 P22748 3/20 0.50
▸ TYR P14679 2/20 0.50
▸ CA12 O43570 2/20 0.50
▸ AKR1B10 O60218 2/20 0.50
▸ CA3 P07451 2/20 0.50
▸ AKR1B1 P15121 2/20 0.50
▸ CA6 P23280 2/20 0.50
▸ DPP4 P27487 2/20 0.50
▸ CA5A P35218 2/20 0.50
▸ CA7 P43166 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30353413 1.00 BACE1 (0.62) BACE1MIFAKR1C3AKR1C2EIF2AK2
SCHEMBL30353445 1.00 BACE1 (0.62) BACE1MIFAKR1C3AKR1C2EIF2AK2
SCHEMBL1804320 1.00 BACE1 (0.62) BACE1MIFAKR1C3AKR1C2EIF2AK2
SCHEMBL16848342 0.85 MIF (0.64) BACE1MIFAKR1C3AKR1C2EIF2AK2
SCHEMBL16848343 0.85 MIF (0.64) BACE1MIFAKR1C3AKR1C2EIF2AK2
SCHEMBL31158251 0.85 MIF (0.64) BACE1MIFAKR1C3AKR1C2EIF2AK2
SCHEMBL18075746 0.84 BACE1 (0.60) BACE1MIFTYRALDH1A1MAPT
SCHEMBL1647148 0.84 BACE1 (0.85) BACE1AKR1B10AKR1B1ALDH1A1MAPT
SCHEMBL1647145 0.84 BACE1 (0.85) BACE1AKR1B10AKR1B1ALDH1A1MAPT
SCHEMBL30353444 0.84 BACE1 (0.60) BACE1MIFTYRALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3490970-B1 COMPOSITIONS FOR THE TREATMENT OF PULMONARY FIBROSIS VECTUS BIOSYSTEMS LTD (AU) 2023-09-13 — — EP disclosed
CN-109661387-B Composition for treating pulmonary fibrosis 维克图斯生物系统有限公司 2023-05-30 — — CN disclosed
US-11401245-B2 Compositions for the treatment of pulmonary fibrosis VECTUS BIOSYSTEMS LIMITED (AU) 2022-08-02 — — US disclosed
US-20210130301-A1 COMPOSITIONS FOR THE TREATMENT OF PULMONARY FIBROSIS VECTUS BIOSYSTEMS LIMITED (AU) 2021-05-06 — — US disclosed
EP-3271326-B1 COMPOSITIONS FOR THE TREATMENT OF KIDNEY AND/OR LIVER DISEASE VECTUS BIOSYSTEMS LTD (AU) 2020-10-28 — — EP disclosed
US-10544083-B2 GPBP inhibition using Q2 peptidomimetics UNIVERSITAT DE VALÈNCIA (ES) 2020-01-28 — — US disclosed
EP-3490970-A1 COMPOSITIONS FOR THE TREATMENT OF PULMONARY FIBROSIS Vectus Biosystems Limited (AU) 2019-06-05 — — EP disclosed
US-20180179139-A1 GPBP inhibition using Q2 peptidomimetics FIBROSTATIN, S.L. (ES) 2018-06-28 — — US disclosed
WO-2018018091-A1 COMPOSITIONS FOR THE TREATMENT OF PULMONARY FIBROSIS VECTUS BIOSYSTEMS LIMITED (AU) 2018-02-01 — — WO disclosed
EP-3271326-A1 COMPOSITIONS FOR THE TREATMENT OF KIDNEY AND/OR LIVER DISEASE Vectus Biosystems Limited (AU) 2018-01-24 — — EP disclosed
US-20160083327-A1 GPBP inhibition using Q2 peptidomimetics JUAN SAUS (ES) 2016-03-24 — — US disclosed
US-9199936-B2 GPBP inhibition using Q2 peptidomimetics Fibrostatin Sociedad Limitada (ES) 2015-12-01 — — US disclosed
EP-2496544-B1 GPBP INHIBITION USING Q2 PEPTIDOMIMETICS FIBROSTATIN S L (SE) 2014-08-20 — — EP disclosed
US-20140080852-A1 GPBP inhibition using Q2 peptidomimetics FIBROSTATIN, S.L. (ES) 2014-03-20 — — US disclosed
US-8586776-B2 GPBP inhibition using Q2 peptidomimetics FIBROSTATIN, S.L. (ES) 2013-11-19 — — US disclosed
EP-2496544-A1 GPBP INHIBITION USING Q2 PEPTIDOMIMETICS Fibrostatin, S.L. (SE) 2012-09-12 — — EP disclosed
WO-2011054530-A1 GPBP INHIBITION USING Q2 PEPTIDOMIMETICS FIBROSTATIN, S.L. (ES) 2011-05-12 — — WO disclosed
US-20110105545-A1 GPBP inhibition using Q2 peptidomimetics FIBROSTATIN, S.L. (ES) 2011-05-05 — — US disclosed
EP-0028063-B1 PHENOL DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM GLAXO GROUP LIMITED (GB) 1984-06-13 — — EP disclosed
EP-0028063-A1 Phenol derivatives, processes for their preparation and pharmaceutical compositions containing them GLAXO GROUP LIMITED (GB) 1981-05-06 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10544083-B2 GPBP inhibition using Q2 peptidomimetics HSP90B1, ERP44, HSPA5 BACE1 1355/4885MIF 1941/4885AKR1C3 3765/4885
US-20140080852-A1 GPBP inhibition using Q2 peptidomimetics HSP90B1, ERP44, HSPA5 BACE1 1355/4885MIF 1941/4885AKR1C3 3765/4885
US-11401245-B2 Compositions for the treatment of pulmonary fibrosis ELANE, MMP1, CCL11 BACE1 4100/4885MIF 243/4885AKR1C3 2082/4885
US-20110105545-A1 GPBP inhibition using Q2 peptidomimetics HSP90B1, ERP44, HSPA5 BACE1 1355/4885MIF 1941/4885AKR1C3 3765/4885
US-20180179139-A1 GPBP inhibition using Q2 peptidomimetics HSP90B1, ERP44, HSPA5 BACE1 1355/4885MIF 1941/4885AKR1C3 3765/4885
US-20160083327-A1 GPBP inhibition using Q2 peptidomimetics HSP90B1, ERP44, HSPA5 BACE1 1355/4885MIF 1941/4885AKR1C3 3765/4885
US-20210130301-A1 COMPOSITIONS FOR THE TREATMENT OF PULMONARY FIBROSIS ELANE, MMP1, CCL11 BACE1 4100/4885MIF 243/4885AKR1C3 2082/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.